The experience of anti-b-cell therapy with rituximab in children with chronic inflammatory demyelinating polyradiculoneuropathy with a description of the clinical case
https://doi.org/10.18705/2782-3806-2024-4-4-319-328
EDN: EATMDN
Abstract
Chronic inflammatory demyelinating polyneuropathy, which occurs in childhood, is usually treatable with the use of standard immunosuppressive drugs. Patients with refractory course may have disabling complications and need biological therapy. The article provides information about the disease and a description of a case refractory to standard therapy with a good response to biological therapy with rituximab.
About the Authors
N. А. Lyubimova
Almazov National Medical Research Centre; Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Natalia A. Lyubimova, Ph.D. of Medical Sciences, rheumatologist
pediatric department No 1
197314; Akkuratova str., 2; Saint Petersburg
T. M. Pervunina
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Tatiana M. Pervunina, MD., professor, Pediatrician, Director of the Institute
Institute of Perinatology and Pediatrics
Saint Petersburg
K. A. Seel
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Kristina A. Seel, Neurologist
Outpatient Advisory Department for Children
Saint Petersburg
M. M. Kostik
Almazov National Medical Research Centre; Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Mikhail M. Kostik, professor
hospital pediatry department
Saint Petersburg
References
1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242–268. DOI: 10.1111/jns.12455.
2. Tsoumanis P, Kitsouli A, Stefanou C, et al. Chronic Inflammatory Demyelinating Polyneuropathy and Evaluation of the Visual Evoked Potentials : A Review of the Literature. Medicina (Kaunas). 2023 Dec 13;59(12):2160. DOI: 10.3390/medicina59122160.
3. Łukawska M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: Diagnosis and Management. A Single-Center Experience. Front Neurol. 2021 Jul 2;12:667378. DOI: 10.3389/fneur.2021.667378. Erratum in: Front Neurol. 2022 Jan 21;12:784144.
4. Buch MH, Smolen JS, Betteridge N, et al. Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909–20. DOI: 10.1136/ard.2010.144998.
5. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68. DOI: 10.1038/sj.onc.1206939.
6. Fatehi F, Okhovat AA, Panahi A, et al. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst. 2021 Dec;26(4):469–474. DOI: 10.1111/jns.12461. Epub 2021 Sep 10.
7. Hu J, Sun C, Lu J, et al. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review and meta-analysis. J Neurol. 2022 Mar;269(3):1250–1263. DOI: 10.1007/s00415-021-10646-y. Epub 2021 Jun 12.
8. Muley SA, Jacobsen B, Parry G, et al. Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020 May;61(5):575–579. DOI: 10.1002/mus.26804. Epub 2020 Jan 21.
9. Nepal G, Shing YK, Yadav JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: A meta-analysis. Acta Neurol Scand. 2020 Nov;142(5):449–459. DOI: 10.1111/ane.13291. Epub 2020 Jun 16.
10. Yiu EM, Shield LK, Tewierik C, et al. Rituximab for treatment of refractory childhood chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol [Internet]. 2008 [cited 2024 Aug 28];119(3). Available from: https://findanexpert.unimelb.edu.au/scholarlywork/1641064-rituximab-for-treatment-of-refractory-childhood-chronic-inflammatory-demyelinating-polyneuropathy
11. D’Amico A, Catteruccia M, De Benedetti F, et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol. 2012 May;16(3):301–3. DOI: 10.1016/j.ejpn.2011.08.002. Epub 2011 Sep 7.
12. Ware TL, Kornberg AJ, Rodriguez-Casero MV, et al. Childhood chronic inflammatory demyelinating polyneuropathy: an overview of 10 cases in the modern era. J Child Neurol. 2014 Jan;29(1):43–8. DOI: 10.1177/0883073812471719. Epub 2013 Jan 29.
13. Desai J, Ramos-Platt L, Mitchell WG. Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions. Ann Indian Acad Neurol. 2015 Jul-Sep;18(3):327–30. DOI: 10.4103/0972-2327.160065.
14. Stevens JAE, Llewelyn G, Hartley L. Rituximab as an adjunct to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Paediatr Neurol. 2017 Jun;21:e114.
15. De Simoni D, Ricken G, Winklehner M, et al. Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy. Neurology - Neuroimmunology Neuroinflammation. 2020;7(4): e763–. DOI:10.1212/NXI.0000000000000763.
16. Ko YJ, Shim YK, Kim WJ, et al. The Efficacy and Safety of Rituximab for the Treatment of Pediatric Autoimmune Neuroinflammatory Disorders at a Single Center. Ann Child Neurol. 2020;28(1):30–36.
17. Godil J, Barrett MJ, Ensrud E, et al. Refractory CIDP: Clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020 Nov 15;418:117098. DOI: 10.1016/j.jns.2020.117098. Epub 2020 Aug 15.
18. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014 Jul 8;83(2):142–50. DOI: 10.1212/WNL.0000000000000570. Epub 2014 Jun 11.
19. Nguyen AT, Cotteret C, Durrleman C, et al. Indications and Safety of Rituximab in Pediatric Neurology: A 10-Year Retrospective Study, Pediatric Neurology. 2022. Vol. 137. P. 41–48. ISSN 0887-8994. doi: 10.1016/j.pediatrneurol.2022.08.004
20. Ghezzi A, Banwell B, Bar-Or A, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal. 2021;27(12):1814–1822. DOI: 10.1177/1352458520932798.
21. Dou X, Li D, Wu Y, et al. Efficacy and Safety of Rituximab in Chinese Children With Refractory Anti-NMDAR Encephalitis. Front Neurol. 2020 Dec 14;11:606923.
Review
For citations:
Lyubimova N.А., Pervunina T.M., Seel K.A., Kostik M.M. The experience of anti-b-cell therapy with rituximab in children with chronic inflammatory demyelinating polyradiculoneuropathy with a description of the clinical case. Russian Journal for Personalized Medicine. 2024;4(4):319-328. (In Russ.) https://doi.org/10.18705/2782-3806-2024-4-4-319-328. EDN: EATMDN
Views:
87
Email this article 